Ontario’s Life Sciences Council appoints experts including OBIO's CEO
Dr. Maura Campbell, President and CEO of OBIO® has graciously accepted an appointment to the Ontario Life Sciences Council by the Honourable Victor Fedeli, Minister of Economic Development, Job Creation and Trade.
Dr. Campbell joins a team of industry experts on the council:
Dr. Jason Field (Chair) – President and CEO of Life Sciences Ontario, Dr. Dozie Amuzie – Head of Johnson & Johnson Innovation for JLABS Canada, Dr. Maura Campbell – CEO of the Ontario Bioscience Innovation Organization, Nicole DeKort – President and CEO of Medtech Canada, Pamela Fralick – President of Innovative Medicines Canada, Elliot Fung – Executive Director of Medical Innovation Xchange, Jim Keon – President of the Canadian Generic Pharmaceutical Association, Cameron Love – President and CEO of The Ottawa Hospital, Dr. Michael May – President and CEO of the Centre for Commercialization of Regenerative Medicine, Dr. Derek Newton – Assistant Vice-President, Innovation, Partnerships and Entrepreneurship at the University of Toronto, Dr. David O’Neill – President of FACIT, Dr. Jane Philpott – Dean of the Faculty of Health Sciences and Director of the School of Medicine at Queen’s University and CEO of the Southeastern Ontario Academic Medical Organization.
The forward-looking Life Sciences Council will focus on long-term growth and competitiveness in medical technology, pharma/biotech, digital health and personal protective equipment (PPE) sub-sectors.
The Council will be tasked to collaboratively work together on a plan to make Ontario a top hub for innovation growth and life sciences investments. It will also identify opportunities for Ontario to work with provincial and federal counterparts to improve regulatory processes and incentives to advance the pharmaceutical sector and improve patient access to innovative medicines.
As President and CEO of OBIO®, Dr. Campbell is dedicated to advancing health technology innovation and commercialization of early-stage companies, including OBIO® members, through ecosystem building, advocacy and programming. With over 30 years of experience in key sectors of biotech, and as CEO of OBIO®, Dr. Campbell understands the challenges that early-stage health science companies face when commercializing and driving adoption of their innovation in Ontario. Dr. Campbell and OBIO® are excited and thankful for the opportunity to bring our members’ perspectives to the Council and work with the Ministry on the support required for the industry to flourish.
To learn more about Ontario’s newly-established Life Sciences Council: